Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal  

Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.

• Source: Biospace
• 526
• January 8, 2018